sedation. Use Caution/Monitor.ofloxacindesipramine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.olanzapineolanzapine and desipramine both increase sedation. Use Caution/Monitor.olanzapine and desipramine both increase QTc interval. Use Caution/Monitor.oliceridinedesipramine, oliceridine. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely.desipramine increases toxicity of oliceridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.olodaterol inhaleddesipramine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmiasopium tinctureopium tincture and desipramine both increase sedation. Use Caution/Monitor.orphenadrinedesipramine and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.orphenadrine and desipramine both increase sedation. Use Caution/Monitor.osilodrostatosilodrostat and desipramine both increase QTc interval. Use Caution/Monitor.osimertinibosimertinib and desipramine both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.oxazepamoxazepam and desipramine both increase sedation. Use Caution/Monitor.oxybutyninoxybutynin and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin topicaloxybutynin topical and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutynin transdermaloxybutynin transdermal and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.oxycodoneoxycodone and desipramine both increase sedation. Use Caution/Monitor.oxymetazoline intranasaldesipramine increases effects of oxymetazoline intranasal by pharmacodynamic synergism. Use Caution/Monitor. TCAs inhibit norepinephrine uptake in adrenergic neurons, thereby increasing synaptic norepinephrine levels. Coadministration with alpha1 agonists may cause increased adrenergic receptor stimulation. When oxymetazoline is combined with intranasal tetracaine for dental anesthesia, avoid or use alternant anesthetic in patients taking TCAs.oxymorphoneoxymorphone and desipramine both increase sedation. Use Caution/Monitor.ozanimodozanimod and desipramine both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.paliperidonedesipramine and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.paliperidone and desipramine both increase sedation. Use Caution/Monitor.pancuroniumpancuronium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.panobinostatpanobinostat will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Panobinostat can increase the levels and effects of sensitive CYP2D6 substrates or those with a narrow therapeutic index CYP2D6.papaveretumpapaveretum and desipramine both increase sedation. Use Caution/Monitor.papaverinedesipramine and papaverine both increase sedation. Use Caution/Monitor.parecoxibparecoxib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.paroxetinedesipramine and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.pasireotidedesipramine and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.pazopanibdesipramine and pazopanib both increase QTc interval. Use Caution/Monitor.peginterferon alfa 2bpeginterferon alfa 2b, desipramine. Other (see comment). Use Caution/Monitor. Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.pentazocinepentazocine and desipramine both increase sedation. Use Caution/Monitor.desipramine and pentazocine both increase serotonin levels. Modify Therapy/Monitor Closely.pentobarbitalpentobarbital and desipramine both increase sedation. Use Caution/Monitor.perphenazineperphenazine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.perphenazine and desipramine both increase sedation. Use Caution/Monitor.phendimetrazinedesipramine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenobarbitalphenobarbital and desipramine both increase sedation. Use Caution/Monitor.phenterminedesipramine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrinedesipramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrine ophthalmicdesipramine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.phenylephrine POdesipramine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .pholcodinedesipramine and pholcodine both increase sedation. Use Caution/Monitor.pimozidepimozide and desipramine both increase sedation. Use Caution/Monitor.pirbuteroldesipramine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.posaconazoledesipramine and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.pralidoximepralidoxime and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.pregabalinpregabalin, desipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.primidoneprimidone and desipramine both increase sedation. Use Caution/Monitor.prochlorperazineprochlorperazine and desipramine both increase QTc interval. Use Caution/Monitor.prochlorperazine and desipramine both increase sedation. Use Caution/Monitor.promethazinepromethazine and desipramine both increase QTc interval. Use Caution/Monitor.promethazine and desipramine both increase sedation. Use Caution/Monitor.propafenonepropafenone will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.propanthelinepropantheline and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.propofolpropofol and desipramine both increase sedation. Use Caution/Monitor.propylhexedrinedesipramine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.protriptylinedesipramine and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramine and protriptyline both increase sedation. Use Caution/Monitor.quazepamquazepam and desipramine both increase sedation. Use Caution/Monitor.quetiapinequetiapine and desipramine both increase sedation. Use Caution/Monitor.quetiapine, desipramine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.quinacrinequinacrine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.quininedesipramine and quinine both increase QTc interval. Use Caution/Monitor.ramelteondesipramine and ramelteon both increase sedation. Use Caution/Monitor.ranolazineranolazine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.desipramine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.rapacuroniumrapacuronium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.remimazolamremimazolam, desipramine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.rifabutinrifabutin decreases levels of desipramine by increasing metabolism. Use Caution/Monitor.rilpivirinerilpivirine increases toxicity of desipramine by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.risperidonedesipramine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.risperidone and desipramine both increase sedation. Use Caution/Monitor.ritonavirritonavir will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.rizatriptanrizatriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.rocuroniumrocuronium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.rolapitantrolapitant will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration.romidepsindesipramine and romidepsin both increase QTc interval. Modify Therapy/Monitor Closely.salmeteroldesipramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.SAMedesipramine and SAMe both increase serotonin levels. Modify Therapy/Monitor Closely.scopolaminescopolamine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.scullcapdesipramine and scullcap both increase sedation. Use Caution/Monitor.secobarbitalsecobarbital and desipramine both increase sedation. Use Caution/Monitor.selpercatinibselpercatinib increases toxicity of desipramine by QTc interval. Use Caution/Monitor.sertralinesertraline will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely.sevofluranesevoflurane and desipramine both increase sedation. Use Caution/Monitor.sevoflurane and desipramine both increase QTc interval. Use Caution/Monitor.shepherd's pursedesipramine and shepherd's purse both increase sedation. Use Caution/Monitor.sodium sulfate/?magnesium sulfate/potassium chloridesodium sulfate/?magnesium sulfate/potassium chloride increases effects of desipramine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycoldesipramine, sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.sodium sulfate/potassium sulfate/magnesium sulfatesodium sulfate/potassium sulfate/magnesium sulfate increases effects of desipramine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.solifenacinsolifenacin and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacin and desipramine both increase QTc interval. Use Caution/Monitor.sorafenibsorafenib and desipramine both increase QTc interval. Use Caution/Monitor.stiripentolstiripentol, desipramine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.sufentanilsufentanil and desipramine both increase sedation. Use Caution/Monitor.sufentanil SLsufentanil SL, desipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.sulfamethoxazoledesipramine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.sumatriptansumatriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.sumatriptan intranasalsumatriptan intranasal and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.suvorexantsuvorexant and desipramine both increase sedation. Modify Therapy/Monitor Closely. Dosage adjustments of suvorexant and concomitant CNS depressants may be necessarytacrolimusdesipramine and tacrolimus both increase QTc interval. Use Caution/Monitor.tamsulosindesipramine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.desipramine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.tapentadoltapentadol and desipramine both increase sedation. Use Caution/Monitor.desipramine and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely.telavancindesipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.temazepamtemazepam and desipramine both increase sedation. Use Caution/Monitor.terbinafineterbinafine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug.terbutalinedesipramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.tetrabenazinetetrabenazine and desipramine both increase QTc interval. Use Caution/Monitor.thioridazinethioridazine and desipramine both increase sedation. Use Caution/Monitor.thiothixenethiothixene and desipramine both increase sedation. Use Caution/Monitor.desipramine and thiothixene both increase QTc interval. Use Caution/Monitor.thyroid desiccatedthyroid desiccated increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.tiotropiumtiotropium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.tipranavirtipranavir will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.tofacitinibdesipramine increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No specific dose adjustment recommended when tofacitinib coadministered with moderate CYP3A4 inhibitors; decrease tofacitinib dose if coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors.tolterodinetolterodine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.topiramatedesipramine and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadoltramadol and desipramine both increase sedation. Use Caution/Monitor.desipramine and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely.trazodonedesipramine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramine and trazodone both increase sedation. Use Caution/Monitor.triazolamtriazolam and desipramine both increase sedation. Use Caution/Monitor.triclofostriclofos and desipramine both increase sedation. Use Caution/Monitor.trifluoperazinetrifluoperazine and desipramine both increase sedation. Use Caution/Monitor.trihexyphenidyltrihexyphenidyl and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.trimethoprimdesipramine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.trimipraminedesipramine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramine and trimipramine both increase sedation. Use Caution/Monitor.triprolidinetriprolidine and desipramine both increase sedation. Use Caution/Monitor.tropisetrondesipramine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.trospium chloridetrospium chloride and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.valbenazinevalbenazine and desipramine both increase QTc interval. Use Caution/Monitor.valerianvalerian and desipramine both increase sedation. Use Caution/Monitor.vecuroniumvecuronium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.venlafaxinevenlafaxine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.desipramine and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.voclosporinvoclosporin, desipramine. Either increases effects of the other by QTc interval. Use Caution/Monitor.voriconazoledesipramine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.xylometazolinedesipramine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.yohimbinedesipramine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ziconotidedesipramine and ziconotide both increase sedation. Use Caution/Monitor.ziprasidoneziprasidone and desipramine both increase sedation. Use Caution/Monitor.zolmitriptanzolmitriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.Minor (98)acarbosedesipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.amobarbitalamobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.anticholinergic/sedative combosanticholinergic/sedative combos and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.atracuriumatracurium and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.atropineatropine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.desipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.atropine IV/IMdesipramine increases levels of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.bazedoxifene/conjugated estrogensbazedoxifene/conjugated estrogens, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects,